American Society Of Clinical Oncology

ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGHRESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE.

QUALITY OF CARE: SEE SCHEDULE O

SCIENTIFIC AND MEDICAL EDUCATION: SEE SCHEDULE O

SCIENTIFIC PUBLICATIONS: SEE SCHEDULE O

1. MEMBERS SERVICES: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 45,000 MEMBERS, IN COLLABORATION WITH ITS AFFILIATE, ASCO ASSOCIATION, D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY (ASSOCIATION). ASCO AND THE ASSOCIATION HAVE RECIPROCAL MEMBERSHIP, MEANING THAT EACH MEMBER IS A MEMBER OF BOTH ASCO AND THE ASSOCIATION. ASCO'S MEMBERS VOLUNTEER TO PROVIDE EXPERTISE FOR EDUCATION, PRACTICE GUIDELINES, POLICY, AND OTHER ONCOLOGY LEADERSHIP ACTIVITIES.2. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH-RELATED ACTIVITIES INCLUDE:- ORIGINAL RESEARCH: ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. ITS MAJOR CLINICAL TRIAL, TAPUR, IS TESTING THE SAFETY AND EFFICACY OF FDA- APPROVED, TARGETED ANTI-CANCER THERAPIES IN OTHER CANCER TYPES FOR PATIENTS WITH AN INDICATIVE GENOMIC ALTERATION. IN 2020, ASCO LAUNCHED A REGISTRY TO COLLECT AND ANALYZE THE IMPACT OF COVID-19 ON CANCER PATIENT OUTCOMES. - SCIENTIFIC/RESEARCH COLLABORATIONS: ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE- BASED PATIENT CARE. THIS INCLUDES AN ASCO-FDA COLLABORATION TO JOINTLY HOST PUBLIC WORKSHOPS ON EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES.- RESEARCH GRANTS AND AWARDS: ASCO MAKES GRANTS TO ITS 501(C)(3) AFFILIATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CONQUER CANCER) TO FUND COMPETITIVELY AWARDED RESEARCH GRANTS AND AWARDS. MOST OF THESE GRANTS SUPPORT THE INDEPENDENT RESEARCH INITIATIVES OF CLINICAL INVESTIGATORS.3. CANCER POLICY: ASCO'S POLICY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY AND EQUITABLE CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY DEVELOPS POSITIONS ADDRESSING ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OFONCOLOGY AND PATIENT CARE. ASCO'S POLICY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINELY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE.4. PATIENT INFORMATION AND OTHER: ASCO PROVIDES IMPORTANT INFORMATION TO THE PUBLIC FREE OF CHARGE THROUGH ITS AWARD-WINNING PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), THROUGH A MOBILE APPLICATION, AND OTHER PATIENT EDUCATION MATERIALS. CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. CANCER.NET PROVIDES ONCOLOGIST- APPROVED INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. THE SITE OFFERS COMPREHENSIVE GUIDES TO MORE THAN 120 TYPES OF CANCER AND CANCER-RELATED SYNDROMES, INCLUDING DISEASE-SPECIFIC TREATMENT AND SIDE EFFECTS INFORMATION. EXTENSIVE INFORMATION CAN BE FOUND ON NAVIGATING CANCER CARE, COPING WITH CANCER, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, SURVIVORSHIP, AND RESEARCH AND ADVOCACY; SELECT CONTENT IS AVAILABLE IN SPANISH, CHINESE, PORTUGUESE, ROMANIAN, ARABIC, GREEK, AND ARMENIAN. CANCER.NET ALSO FEATURES VIDEOS, PODCASTS, AND AN AWARD-WINNING BLOG.